Explore. Experience.

Experience
Overview

This infographic is a comprehensive interactive application that allows you to explore the key characteristics of Linagliptin (Trajenta®) that make it an important choice for the treatment of a broad range of type 2 diabetes patients*¹.

* Indicated for use in adult T2D patients. Linagliptin (Trajenta®) is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.

Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.

10 Years of Simplicity

2021 marks the 10 Year anniversary since the first availability of Linagliptin (Trajenta®). In 2011, Linagliptin (Trajenta®) became registered in more than 30 countries around the world, as a once-daily, always one-dose, DPP4i for the treatment of type 2 diabetes*. Today, physicians in more than 110 countries¹ rely on the simplicity of Linagliptin (Trajenta®) for the treatment of patients with type 2 diabetes.

*Linagliptin (Trajenta®) was approved by the US Food and Drug Administration (FDA) on May 2^nd, 2011; Linagliptin (Trajenta®) was approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on July 1^st, 2011; Linagliptin (Trajenta®) was approved by the European Medicines Agency (EMA) on August 23^rd, 2011; Linagliptin (Trajenta®) was approved by Health Canada on October 3^rd, 2011; Linagliptin (Trajenta®) was approved by the Philippine Food and Drug Administration (FDA) on 28-Feb-2012.

Boehringer Ingelheim, Data on File, 2020.

Years of Exposure

Since the approval of Linagliptin (Trajenta®) in 2011, there have been more than 20 million patient-years of exposure* with linagliptin¹. During this time, physicians worldwide have relied on the simplicity of Linagliptin (Trajenta®) for the treatment of T2D patients. Meanwhile, T2D patients have benefitted from a DPP4 inhibitor with proven efficacy^2,5, a demonstrated CV and kidney safety profile^3-4, and the convenience of a single dose, once daily⁵.

* Patient-years is a measurement that takes into account both the number of patients receiving a prescription for linagliptin and the amount of time each patient takes the prescription. For example, one patient taking linagliptin for one year qualified as one patient-year; similarly, two patients taking linagliptin, each for 6 months, qualifies as one patient-year. Figure estimated based on the number of tablets out of factory.

Boehringer Ingelheim, Data on File, 2020.
Del Prato S, et al. J Diab Compl. 2013;27:274–9.
Rosenstock J, et al. JAMA 2019; 321: 69-79.
Rosenstock J, et al. JAMA. 2019; doi:10.1001/jama.2019.13772.
Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.

Unique CVOT Program^1-4

Physicians have continued to rely on the simplicity of Linagliptin (Trajenta®) in part due to its impressive CVOT program (CARMELINA and CAROLINA), which demonstrated the long-term CV and kidney safety profile of Linagliptin (Trajenta®) in more than 13,000 T2D patients*. In fact, Linagliptin (Trajenta®) is backed by one of the most unique and robust CVOT programs, which included patients with relatively early T2D as well as more severe patients at high risk for CV and/or kidney disease*.

* CARMELINA included 6,979 patients with albuminuria & previous macrovascular disease, and/or impaired kidney function with or without CV comorbidities. CAROLINA® included 6,033 patients with one or more of the following: a) previous vascular disease, b) evidence of vascular-related end-organ damage, c) age: 70 years and d) 2 CV risk factors (smoking, hypertension, T2D duration 10 years, dyslipidemia).

Rosenstock J, et al. JAMA 2019; 321: 69-79.
Rosenstock J, et al. Cardiovasc Diabetol 2018; 17:39.
Marx N, et al. Diab Vasc Res. 2015; 12: 164-74.
Rosenstock J, et al. JAMA. 2019; doi:10.1001/jama.2019.13772.

Over 13,000 T2D patients in 2 CVOTs*^1,4

Broad Range of T2D Patients

Linagliptin (Trajenta®) is the only globally approved DPP4 inhibitor that does not require dose adjustment¹. Unlike most DPP4 inhibitors, Linagliptin (Trajenta®) is primarily excreted via a non-kidney route. Whether a T2D patient is 50 years old and recently diagnosed, or 80 years old and living with type 2 diabetes for many years, Linagliptin (Trajenta®) offers convenience through one dose, once daily, always 5mg. This is one of the reasons why physicians have continued to rely on the simplicity of Linagliptin (Trajenta®) for a broad range of T2D patients.

Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.

Simplicity means…

Relying on a DPP4i that continues to generate positive experience for physicians worldwide

When you decide to use a DPP4i, consider how Linagliptin (Trajenta®) has helped simplify T2D treatment for more than 10 years, with over 20 million patient-years of exposure*¹, and a uniquely broad clinical dataset².

* Patient-years is a measurement that takes into account both the number of patients receiving a prescription for linagliptin and the amount of time each patient takes the prescription. For example, one patient taking linagliptin for one year qualified as one patient-year; similarly, two patients taking linagliptin, each for 6 months, qualifies as one patient-year. Figure estimated based on the number of tablets out of factory.

Boehringer Ingelheim, Data on File, 2020.
Linagliptin (TRAJENTA®) PH Prescribing Information. April 2019.

Boehringer Ingelheim (Philippines), Inc.
23rd Floor, BDO Towers Valero Bldg.,
8741 Paseo de Roxas, Bel-Air,
Makati City, Metro Manila
Phone +(632) 8867-0880
Email to us:
BI.SKIES.ph@boehringer-ingelheim.com